Richard Hoffman

Richard Hoffman

Richard Hoffman
+1 617 570 1072

Richard Hoffman is a partner in Goodwin’s Life Sciences group. Mr. Hoffman is a lawyer, consultant and entrepreneur in the life sciences industry, with extensive experience in establishing new companies, negotiating and closing venture capital financings, in-licensing technologies, and developing and implementing corporate and business development strategies. He also has a successful track record in structuring, negotiating, and documenting strategic deals with both public and private companies. He joined the firm in 2016.

Mr. Hoffman was formerly a partner with WilmerHale. He has previously worked in the biotech industry, serving as a legal advisor and business consultant to numerous biotech companies. As principal at R.A. Hoffman Consulting, he provided entrepreneurs and early-stage biotechnology, medical device and healthcare information companies with advice on corporate and business development strategies and tactics.

Prior to his consulting work, Mr. Hoffman served as Vice President of Finance and Business Development at Hybridon, Inc. (now a public company, Idera Pharmaceuticals), and later served in a similar capacity at biotech company Avitech, Inc.


Mr. Hoffman’s practice is focused on privately held and publicly traded emerging growth companies with a strong emphasis on companies across the spectrum of the life sciences industry, including biotechnology, medical devices, diagnostics and healthcare information technology. He often serves as general counsel to his clients, closely advising management teams and boards of directors on a wide variety of matters throughout the company’s life cycle, including company formation, private equity financings, public offerings, mergers and acquisitions, strategic collaborations, commercial transactions, corporate governance and general corporate matters. Mr. Hoffman also regularly represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments and company-initiation activities.

His recent client representations include work with:

  • Blackstone Life Sciences in its $400 million investment to accelerate the future development and commercialization of nadofaragene firadenovec,an investigational gene therapy, with Ferring Pharmaceuticals.
  • Anthos Therapeutics in its $250 million financing by Blackstone Life Sciences and in-license of MAA868 from Novartis.
  • TriNetX in its formation, series preferred financings and its acquisition of Custodix.
  • Kyn Therapeutics in its formation, series preferred financing and global strategic collaboration with Celgene.
  • Syntimmune in its formation, series preferred financings and its $1.2 billion acquisition by Alexion Pharmaceuticals.
  • Deciphera in its series preferred financing, approximately $130 million IPO and approximately $200 million and $400 million follow-on offerings.
  • Cullinan Oncology in the formation and financing of Cullinan Pearl and in-license of TAS6417 from Taiho Pharmaceuticals.
  • Cullinan Oncology in the formation and financing of Cullinan Apollo and in-license of VK-2019 from the Wistar Institute.
  • Ablexis in its business development and licensing efforts, including licenses with Zai Lab, Allogene, Corvidia, Voyager, Memorial Sloan Kettering, Five Prime Therapeutics, Novartis, Janssen and Tri-Institutional Discovery Institute, and the structuring and negotiation of its novel consortium model of initial licenses.
  • Deerfield Management in various venture investments, including the approximately $50 million Series A financing of Solis Therapeutics, $84 million Series B financing of Homology Medicines, $45 million Series B financing of Graybug Vision and $34 million financing of Lumos Pharma.
  • Deerfield Management in new company formation activities, including its formation and approximately $43 million Series A financing of Stelexis.
  • Nuvelution in its collaborative partnership with Teva to develop Austedo® (deutetrabenazine) and its collaborative risk-sharing agreement with Amgen.
  • Cydan in its option and license agreements, including those associated with Tiburio, Imara and Vtesse.
  • Humatics Corporation in its preferred stock financings and its acquisition of 5D Robotics.
  • Innovative Targeting Solutions in its collaboration and licensing activities, including research collaborations with Sanofi and Janssen.
  • Harvard in its $100 million strategic R&D alliance with Deerfield Management through Lab1636.
  • Harvard in its license to Beam Therapeutics of a suite of revolutionary DNA base editing technologies for treating human disease.
  • Harvard in its license to Merck a group of small molecule drug compounds for the treatment of blood cancers, such as AML.
  • TARA Biosystems in its Series A financing and collaboration and licensing activities.
  • Pairwise Plants in its initiation, $25 million Series A financing and R&D collaboration with Monsanto.
  • Arrys Therapeutics in its license of EP4 antagonists from AskAt Inc.
  • Fedora Pharmaceuticals in its $750 million deal with Roche for ex-Japan rights to a novel beta-lactamase inhibitor.
  • Goldfinch Bio in its collaborations with Icahn School of Medicine at Mount Sinai, Vanderbilt University, and NEPTUNE.
  • Neon Therapeutics in its foundational in-licenses from the Broad Institute, Dana Farber Cancer Center and Massachusetts General Hospital.
  • Editas Medicine in its collaboration with Juno.
  • Editas Medicine in its foundational in-licenses from the Broad Institute, Harvard University and Massachusetts Institute of Technology.
  • Editas Medicine in its in-license from Massachusetts General Hospital.
  • ConforMIS in its approximately $140 million IPO.
  • Eleven Biotherapeutics in its approximately $50 million IPO.
  • Ophthotech in its approximately $170 million IPO.




Columbia Law School

Masters of Business Admin

The Wharton School at the University of Pennsylvania

BABiochemical Sciences

Harvard College

(magna cum laude)



  • Massachusetts
  • District of Columbia
  • Maryland

Recognition & Awards

Mr. Hoffman has been recognized by The Best Lawyers in America Best Lawyers for his work in Biotechnology and Life Sciences Practice 2022-2023.


  • Biotechnology Industry Organization: 2016 BIO International Convention San Francisco, California, June 6-9, 2016
  • Biotechnology Industry Organization: 2015 BIO International Convention Philadelphia, Pennsylvania, June 13-18, 2015
  • Biotechnology Industry Organization: 2014 BIO International Convention San Diego, California June 23-26 2014
  • MPM Capital’s 13th Annual Healthcare Leaders Summit Bal Harbour, Florida, May 20-21, 2014